Introduction {#s1}
============

Drug-induced liver injury (DILI) is the primary factor of drug withdrawal and the incidence is increasing ([@B25]), including hepatocellular pattern, cholestatic pattern, and mixed pattern. Serious liver injury associated with Chinese herbal medicines has been reported more frequently as they become more and more popular ([@B25]). For example, the hepatotoxicity of *Polygoni Multiflori Radix* is related to activity inhibition of cytochrome P450 1A2 (CYP1A2) or cytochrome P450 2E1 (CYP2E1) ([@B10]), as well as complex composition and patient factors ([@B36]). It is a challenge in managing DILI, especially when the mechanism is unknown ([@B8]; [@B7]). Understanding the mechanism is essential for predicting and clinically managing drug toxicity.

As an adjuvant therapy for chronic liver disease, OA has displayed anti-tumor, anti-diabetic, and antiviral activity ([@B45]; [@B3]). It is frequently contained in Chinese herbal formulas as a major component of the prescription, but it has also been recorded that OA caused liver injury if given in a small dose for a long time or a large dose for a short time ([@B19]). Unfortunately, the mechanism of OA-induced hepatotoxicity has not been clarified. Thus, it is necessary to inspect the hepatotoxicity mechanism, which not only can minimize the risk of early drug development but provide diagnostic biomarkers for liver toxicity.

Metabolomics has been extensively used for investigating mechanisms at the molecular level in various research fields, e.g., drug metabolism, treatments, toxicology, etc. ([@B21]; [@B18]). Moreover, metabolomics can provide valuable markers for predicting DILI ([@B9]). Using metabolomics, Pannala et al. identified the markers of *acetaminophen*-induced toxicity in rats, and they found that nucleotide, lipid, and amino acid metabolism were the major pathways ([@B27]). Serum and urine metabolomics analysis from *hydrazine*-treated and control rats revealed that hydrazine altered the metabolism pathways of amino acids, glutathione metabolites, vitamins, and fatty acids ([@B1]). At present, liquid chromatography (LC)-mass spectrometry (MS) technology has become the mainstream tool of global metabolomics research because of superior resolution and sensitivity ([@B12]), but the results may be affected by the steps of sample collection, storage, preparation, as well as by matrix effects and the number of samples, further verification of the results through targeted analysis may be the future direction ([@B33]; [@B5]). Currently, few in-depth studies on key metabolic pathways have been conducted after untargeted analysis, but these in-depth mechanisms are very important for the prediction and management of drug toxicities.

In this study, in order to explore the mechanism of OA-induced hepatotoxicity and seek the diagnostic biomarkers, we employed untargeted metabolomics to analyze the metabolic differences in liver tissue after OA (457 mg/kg and 685.5 mg/kg) intragastric administration for 4 consecutive days and then verified the pivotal pathway by targeted metabolomics.

Materials and Methods {#s2}
=====================

Materials {#s2_1}
---------

OA (purity \>99%) was obtained from Sigma-Aldrich ([@B39]). Bile acid standards were purchased from ZZBIO Ltd. ([@B16]). HPLC grade acetonitrile and formic acid were obtained from Thermo Fisher Scientific (CA, USA), ammonium acetate was purchased from Sigma-Aldrich (St. Louis, USA).

Animal Treatment {#s2_2}
----------------

Male C57BL/6J mice (6--8 weeks old) were purchased from SPF Biotechnology Technology Co. Ltd. (Beijing, China). Mice were placed in a 12-h light/dark environment (8:00 a.m. to 8:00 p.m.) and fed normal chow and water ad libitum in the Key Laboratory of Basic Pharmacology of the Ministry of Education at Zunyi Medical University. After 3 days of acclimatization, the mice were randomly divided into the following three groups (n = 6), including control group, OA low-dose group (457 mg/kg, low dose), and OA high-dose group (685.5 mg/kg, high dose). The doses used were based on a previous study ([@B20]). In the control group, 10 ml/kg corn oil was given through intragastric administration once per day for 4 consecutive days. All procedures used in this study were in accordance with the requirements of the Animal Experiment Ethics Committee of Zunyi Medical University.

Serum Biochemical Factors {#s2_3}
-------------------------

Alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and total bile acids (TBA) were analyzed by standard enzymatic assays using commercial kits according to the manufacturer\'s protocols (Jiang-Cheng Biological, China).

Histopathology {#s2_4}
--------------

Liver samples were fixed in 4% neutral buffered formaldehyde solution for 24 h and embedded in paraffin. Livers were cut into 3.5 μm thick sections and the sections were stained with hematoxylin and eosin (H&E).

Untargeted Liver Metabolic Profiling Analysis Using UHPLC- Q Exactive Orbitrap-MS {#s2_5}
---------------------------------------------------------------------------------

### Liver Metabolic Sample Preparation {#s2_5_1}

Liver (100 mg) was homogenized in 300 µl of ice-cold acetonitrile/water (1:1, v/v). Next, 600 µl ice-cold acetonitrile was added to 200 µl of the mixture, followed by centrifugation at 20,627 g at 4°C for 15 min. The supernatant (600 µl) was transferred to a new vial and dried in a centrifugal vacuum freeze dryer. The residue was reconstituted in 200 µl acetonitrile/water containing 0.1% formic acid. After centrifugation at 20,627 g at 4°C for 15 min, the supernatant was transferred to a sample vial for LC-MS analysis. Quality control (QC) samples were prepared by combining equal aliquots of liver, processed in the same way as the analytical samples, and were added to monitor the stability of the LC-MS platform after every eight samples ([@B24]).

### Liver Metabolic Profiling Data Acquisition {#s2_5_2}

Metabolic profiling of liver samples was conducted using a UHPLC-Q Exactive Orbitrap-MS (Thermo Fisher Scientific) fitted with an electrospray ionization (ESI) source. A Hypersil Gold C18 column (100×2.1 mm, 1.9 μm; Thermo Fisher Scientific) was used for metabolite separation. The column temperature was 40°C. Mobile phase A consisted of 0.1% formic acid in water and mobile phase B consisted of acetonitrile with 0.1% formic acid, the elution gradient program used was described in the previous study ([@B11]). The sample injection volume was 3 µl and the flow rate was set at 0.2 ml/min. Data were acquired using Full Scan-ddMS2 scan mode, all samples were analyzed under positive and negative ionization modes, mass parameters of the ESI ion source were set as follows: capillary temperature, 320°C; heater temperature, 300°C; sheath gas flow rate, 35 arb; auxiliary gas flow rate, 10 arb; and scan range, 100--1,500 m/z ([@B13]; [@B41]).

### Multivariate Data Analysis (MDA) {#s2_5_3}

The raw UHPLC-MS data were collected using an Xcalibur workstation (Thermo Fisher Scientific) and imported into Compound Discoverer 2.0 (Thermo Fisher Scientific) for metabolomics analysis and metabolite alignment. The processing parameters were as follows: mass range: 100--1,500 Da; mass tolerance: 5 ppm; retention time tolerance (min): 0.05; and S/N threshold: 3. After processing, the data were imported into excel to carry out MDA.

MDA was performed using SIMCA-P software (version 14.1, Umetrics, Sweden). Principal components analysis (PCA), partial least squares discriminant analysis (PLS-DA) and orthogonal partial least squares discriminant analysis (OPLS-DA) models were used to analyze the data. Variable importance in projection (VIP) \> 1 indicates that a metabolite has an important influence on the group classification, and the independent sample *t*-test was used to assess the significance of the metabolites. Metabolites with VIP \> 1 and *P* \< 0.05 were considered statistically significant differential metabolites.

The metabolites were confirmed by using the following databases: Human Metabolome Database (<http://www.hmdb.ca/>), Kyoto Encyclopedia of Genes and Genomes (KEGG) LIGAND Database (<https://www.genome.jp/kegg/ligand.html>), and Massbank (<https://massbank.eu/MassBank/Search>). Significant bile acids were compared based on standard peak retention time. MetaboAnalyst (<https://www.metaboanalyst.ca/>) was used for metabolic pathway enrichment analysis.

Targeted Liver Bile Acid Analysis Using UHPLC-TSQ-MS {#s2_6}
----------------------------------------------------

### Sample Preparation {#s2_6_1}

The liver bile acid extraction method was described previously ([@B16]). Approximately 100 mg frozen liver was accurately weighed and homogenized in two times the volume of double-distilled deionized water (ddH~2~O; 200 µl for 100 mg). The mixture was centrifuged at 13,500 g for 15 min at 4°C, and 250 µl supernatant was transferred into a new tube. The bile acid extraction was performed with 750 µl acetonitrile and then the mixture was vortexed for 30 s and centrifuged at 13,500 g for 15 min to remove precipitated proteins and other particulates. Finally, 800 µl supernatant was transferred into a clean tube, evaporated to dryness with nitrogen, and stored at -80°C overnight. The residue was then reconstituted with 100 µl methanol/water (50:50, v/v), vortexed for 30 s, and centrifuged at 14,000 g for 10 min at 4°C.

### Bile Acid Standard Solutions and Calibration Curves {#s2_6_2}

Bile acid-free liver tissue was prepared. First, the liver homogenate was obtained by homogenizing the liver tissue in water (1:2, w/v). The liver homogenate was then treated with 150 mg/ml activated charcoal for 6 h to remove the endogenous bile acids ([@B15]; [@B40]). Twenty bile acid standards were diluted with 50% methanol/water to create final concentrations of 4--2000 ng/ml.

### UHPLC-TSQ-MS Method {#s2_6_3}

Bile acids were quantified by first conducting LC separation and then performing MS detection. We used a Hypersil Gold C18 column (100×2.1 mm, 1.9 μm, Thermo Fisher Scientific), a Finnigan Surveyor LC pump, a Finnigan Surveyor autosampler, and a TSQ Quantum triple quadrupole mass spectrometer with an ESI interface (Thermo Fisher Scientific). Mobile phase A consisted of 20% acetonitrile in water (containing 5 mM ammonium acetate), and mobile phase B consisted of acetonitrile with 20% water (containing 5 mM ammonium acetate). The flow rate was 0.3 ml/min. The gradient profile under the final LC conditions was as follows: 0--2 min, 5% B; 2--6 min, 14% B; 6.3 min, 25% B; 6.3--14 min, 50% B; 14--27 min, 95% B; 27--30 min, 100% B; and 30--34 min, 5% B. The injection volume was 3 µl. The column temperature was set at 45°C, and the sample tray temperature was maintained at 4°C. For MS detection, the ESI source was operated in the negative ion mode to produce MS/MS spectra, and Xcalibur 2.0 software was used (Thermo Fisher Scientific). High-purity nitrogen was used as the sheath gas (35 arb) and auxiliary gas (10 arb). The other parameters were as follows: spray voltage, 3.5 kV; capillary temperature, 300°C; scan width for selected reaction monitoring (SRM), 0.5 m/z; and scan time, 0.2 s. The peak width settings for both Q1 and Q3 were 0.7 m/z. The SRM ion pair transitions and collision energy levels of each component are listed in [**Table 1**](#T1){ref-type="table"}.

###### 

Selected reaction monitoring (SRM) transitions and mass spectroscopy (MS) parameters in bile acid analysis.

  Bile acid       Q1 (m/z)   Q3 (m/z)   Collision Energy (V)
  --------------- ---------- ---------- ----------------------
  TUDCA           498.3      80.0       65
  UDCA            391.3      391.3      30
  Nor-DCA         377.3      377.3      20
  β MCA           407.3      407.3      10
  CA              407.3      407.3      30
  TCDCA           498.3      80.0       65
  λ MCA           407.3      407.3      10
  DCA             391.3      391.3      30
  TLCA            482.3      80.0       60
  6,7-diketoLCA   403.3      403.3      10
  GCA             464.3      74.0       37
  7ketoLCA        389.3      389.3      30
  LCA             375.3      375.3      30
  T-βMCA          514.3      80.0       60
  αMCA            407.3      407.3      10
  3βCA            407.3      407.3      25
  CDCA            391.3      391.3      30
  TCA             514.3      80.0       65
  T-αMCA          514.3      80.0       60
  TDCA            498.3      80.0       60

Statistical Analysis {#s2_7}
--------------------

All results were evaluated using SPSS 18.0. All data were assessed using one-way ANOVA or Student\'s *t*-test. *P* \< 0.05 was considered significant. The graphs were generated using GraphPad Prism version 7 (GraphPad Software). Bars represent means ± SEM.

Results {#s3}
=======

OA Induced Hepatotoxicity in C57BL/6J Mice {#s3_1}
------------------------------------------

Compared with the control group, the weight of the mice decreased significantly in low- and high-dose groups (*P* \< 0.05, [**Figure 1A**](#f1){ref-type="fig"}), and there was no significant difference between low dose and high dose. The liver index and gallbladder weight increased (*P* \< 0.05, [**Figures 1B, C**](#f1){ref-type="fig"}), lighter liver color, and gallbladder enlargement were observed after OA administration groups ([**Figure 1D**](#f1){ref-type="fig"}), but without any statistical significance between low dose and high dose. The levels of ALT, AST, ALP, TBA increased by 95-, 10-, 1.4-, 12-fold in the low-dose group and by 129-, 20-, 2.3-, 18-fold in the high-dose group compared with the control group (*P* \< 0.05, [**Figure 2A**](#f2){ref-type="fig"}), respectively. The liver pathology was agreed with the serum biochemical results, hepatocyte necrosis (black arrows) were evident in both low- and high-dose groups ([**Figure 2B**](#f2){ref-type="fig"}). The results suggested that OA-mediated liver injury was mainly associated with the changes of bile acids.

![Effects of OA administration on **(A)** body weight, **(B)** liver index, **(C)** gallbladder weight, and **(D)** liver and gallbladder morphology in C57BL/6J mice. Data are expressed as mean ± SEM (n = 6). ^\*^ *P* \< 0.05 *vs* the control group.](fphar-11-00747-g001){#f1}

![Serum biochemical factors **(A)** and liver histopathology **(B)** after OA administration in C57BL/6J mice. Data are expressed as mean ± SEM (n = 6). ^\*^ *P* \< 0.05, ^\*\*^ *P* \< 0.01 and ^\*\*\*^ *P* \< 0.001 *vs* the control group. Histological sections were stained with H&E (×200). Arrows represent hepatocellular cell death.](fphar-11-00747-g002){#f2}

OA Altered Liver Metabolic Profile {#s3_2}
----------------------------------

In the work, the PCA score plot of all samples, including QC samples, was applied to demonstrate the LC-MS system stability ([**Figure S1**](#SM1){ref-type="supplementary-material"}), QC samples were clustered close to the center. The PLS-DA statistical method was employed to assess the metabolic changes among all groups. The cumulative R^2^Y and Q^2^ of PLS-DA model indicated good prediction and reliability ([**Figure 3A**](#f3){ref-type="fig"}), hinting that endogenous metabolites changed in the two administration groups and in the control group.

![**(A)** Results of multiple pattern recognition methods regarding liver metabolites after OA administration in C57BL/6J mice, showing PLS-DA score plot (n = 6, R^2^Y = 0.99, R^2^X = 0.664, Q^2^ 543 = 0.878). OPLS score plot of **(B)** low-dose group (n = 6, R^2^Y = 0.969, R^2^X = 0.663, Q^2^ = 0.749) and **(E)** high-dose group (n = 6, R^2^Y = 0.988, R^2^X = 0.634, Q^2^ = 0.945) with the control group. Permutation test results of **(C)** low-dose group (R^2^ = 0.99, Q^2^ = −0.0654) and **(F)** high-dose group (R^2^ = 0.779, Q^2^ = −0.353) with the control group. OPLS S-plot of **(D)** low-dose group and **(G)** high-dose group with the control group. Each dot in the S-plot represents an ion. Ions far away from the origin are potential biomarkers.](fphar-11-00747-g003){#f3}

To completely distinguish metabolites in the OA groups from those in the control group and identify potential biomarkers, we used OPLS-DA ([**Figures 3B, E**](#f3){ref-type="fig"}) to eliminate irrelevant spectral changes. The R^2^Y and Q^2^ parameters represent the reliability of the multiple pattern recognition methods. R^2^Y represents how well the model fits the data, and Q^2^ indicates the predictive accuracy of the model. The results of the permutation tests (200 permutations) showed that the two models were not overfitted and reflected the metabolic changes (intercepts: R^2^ = 0.99, Q^2^ = −0.0654, and R^2^ = 0.779, Q^2^ = −0.353) ([**Figures 3C, F**](#f3){ref-type="fig"}). The corresponding OPLS S-plots ([**Figures 3D, G**](#f3){ref-type="fig"}) in turn showed the contributions of different variables. Ions far away from the origin might be potential biomarkers. Finally, eleven significantly differential metabolites were identified between the low-dose group and the control group, fifteen significantly differential metabolites were identified between the high-dose group and the control group. All metabolite information was listed in [**Table 2**](#T2){ref-type="table"}.

###### 

Identified differential metabolites in the liver of C57BL/6J mice with or without OA administration.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  NO.   Name                         RT\     Formula                M/Z                 Relative content   Ion               Metabolic pathway         
                                     (min)                                                                                                             
  ----- ---------------------------- ------- ---------------------- ------------------- ------------------ ----------------- ------------------- ----- -----------------------------------------------------------------------------------
  1     Valine                       2.69    C~5~H~11~NO~2~         118.0862            0.0724 ± 0.0041    0.1355 ± 0.0051   /                   \+    Valine, leucine and isoleucine degradation; Pantothenate and CoA biosynthesis

  2     D-Mannose                    2.11    C~6~H~12~O~6~          179.0559            0.1552 ± 0.0073    /                 0.0263 ± 0.0010     --    Biosynthesis of alkaloids derived from ornithine, lysine, and nicotinic acid

  3     Pantothenic acid             6.65    C~9~H~17~NO~5~         220.1177/218.1031   0.0388 ± 0.0030    /                 0.2724 ± 0.0132     +/-   Beta-Alanine metabolism; Pantothenate and CoA biosynthesis

  4     Tryptophan                   6.77    C~11~H~12~N~2~O~2~     205.0969            0.0585 ± 0.0039    0.1258 ± 0.0010   /                   \+    Tryptophan metabolism

  5     Taurochenodeoxycholic acid   11.93   C~26~H~45~NO~6~S       498.29              0.0097 ± 0.0026    0.0937 ± 0.0084   0.1080 ± 0.0039     --    Primary bile acid biosynthesis; Bile secretion

  6     Uracil                       3.44    C~4~H~4~N~2~O~2~       113.0346            0.0552 ± 0.0043    /                 0.1753 ± 0.0119     \+    Pyrimidine metabolism; Beta-Alanine metabolism; Pantothenate and CoA biosynthesis

  7     Allantoin                    2.21    C~4~H~6~N~4~O~3~       157.0365            0.00381 ± 0.0022   /                 0.3413 ± 0.0280     --    Purine metabolism

  8     Taurodeoxycholic acid        12.88   C~26~H~45~NO~6~S       498.2896/500.3037   0.1897 ± 0.0110    0.0472 ± 0.0135   0.0187 ± 0.0038     +/-   Primary bile acid biosynthesis; Bile secretion

  9     4-Hydroxybutyric acid        5.11    C~4~H~8~O~3~           103.04              0.0631 ± 0.0056    /                 0.1705 ± 0.074      --    Butanoate metabolism

  10    2-Hydroxyvaleric acid        7.09    C~5~H~10~O~3~          117.0557            0.0331 ± 0.0019    /                 0.2376 ± 0.0152     --    Other

  11    Glycocholic acid             10.73   C~26~H~43~NO~6~        466.3154/464.3015   0.0079 ± 0.0009    0.0772 ± 0.0102   0.1017 ± 0.0149     +/-   Primary bile acid biosynthesis; Bile secretion

  12    Suberic acid                 7.49    C~8~H~14~O~4~          173.0817            0.0972 ± 0.0052    /                 0.2324 ± 0.0159     --    Other

  13    4′-Phosphopantetheine        6.63    C~11~H~23~N~2~O~7~PS   357.0891            0.0332 ± 0.0037    0.1563 ± 0.0148   0.1500 ± 0.0147     --    Biosynthesis of antibiotics

  14    Citraconic acid              6.61    C~5~H~6~O~4~           129.0192            0.0148 ± 0.0018    0.1159 ± 0.0183   0.2713 ± 0.0206     --    Arginine and proline metabolism

  15    Succinate                    3.60    C~4~H~4~O~4~           115.0037            0.0597 ± 0.0019    0.1395 ± 0.0056   0.1205 ± 0.0116     --    Biosynthesis of alkaloids derived from ornithine, lysine, and nicotinic acid

  16    Deoxycholic acid             16.66   C~24~H~40~O~4~         391.2855            0.0684 ± 0.0063    0.1540 ± 0.0111   /                   --    Primary bile acid biosynthesis; Bile secretion

  17    L-Glutamic acid              2.58    C~5~H~9~NO~4~          148.0604            0.2123 ± 0.0249    0.0535 ± 0.0103   0.0718 ± 0.0134     \+    Arginine and proline metabolism

  18    Citric acid                  2.81    C~6~H~8~O~7~           191.0195            0.0466 ± 0.0020    0.1351 ± 0.0083   0.1331 ± 0.0064     --    Biosynthesis of amino acids
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Characterization of Potential Biomarkers {#s3_3}
----------------------------------------

Detailed relative changes in potential biomarkers were shown in [**Figure 4**](#f4){ref-type="fig"} and [**Figure S2**](#SM2){ref-type="supplementary-material"}. Compared with the control group, taurodeoxycholic acid (TDCA) and L-glutamic acid were downregulated in both low- and high-dose groups (*P* \< 0.05). Valine, tryptophan, taurochenodeoxycholic acid (TCDCA), glycocholic acid (GCA), 4′-phosphopantetheine, citric acid, and succinate were upregulated in the low-dose group (*P* \< 0.05). Compared with the control group, pantothenic acid, 4-Hydroxybutyric acid, 2-Hydroxyvaleric acid, uracil, allantoin, 4′-phosphopantetheine, citric acid, succinate, citraconic acid, and TCDCA were upregulated in the high-dose group (*P* \< 0.05). These differential metabolites could be used to effectively distinguish the groups.

![Detailed relative changes in the relative peak area of potential biomarkers. **(A)** Control group *vs* low-dose group, **(B)** Control group *vs* high-dose group. Data are expressed as mean ± SEM (n = 6). \**P* \< 0.05 *vs* the control group.](fphar-11-00747-g004){#f4}

Metabolic Pathway Analysis {#s3_4}
--------------------------

To further explore the association between the markedly changed metabolites in all OA administration groups and OA hepatotoxicity. MetaboAnalyst was used to reveal the possible metabolic pathways, based on the *P* values (*P* \< 0.05). Among them, amino acid metabolism (beta-alanine metabolism; valine, leucine and isoleucine degradation), energy metabolism (citric acid cycle; pantothenate and CoA biosynthesis), and bile acid metabolism (bile acid biosynthesis) were considered as the pertinent metabolic pathways ([**Figure 5**](#f5){ref-type="fig"}).

![Summary of metabolite set enrichment after OA administration in C57BL/6J mice using MetaboAnalyst.](fphar-11-00747-g005){#f5}

Correlation of Serum Biochemical and Metabolites {#s3_5}
------------------------------------------------

Spearman\'s correlation analysis was performed to explore the relationships between differential metabolites and serum biochemical factors ALT, AST, ALP, TBA ([**Figure 6**](#f6){ref-type="fig"}). There were strong positive correlations among TCDCA, GCA, 4-Hydroxybutyric acid, 2-Hydroxyvaleric acid, and 4′-phosphopantetheine, and strong negative correlations among deoxycholic acid (DCA), TDCA, and D-Mannose. The observation of both positive and negative correlations between bile acids and serum biochemical factors suggested that OA-induced hepatotoxicity was closely correlated with bile acid homeostasis.

![Correlation analysis results of OA-induced liver marker metabolites and biochemical factors (ALT, AST, ALP, and TBA). Red squares indicate a positive correlation, and green squares indicate a negative correlation.](fphar-11-00747-g006){#f6}

Analysis of Bile Acids Using UHPLC-TSQ-MS/MS {#s3_6}
--------------------------------------------

The liver levels of both unconjugated and conjugated bile acids were changed by OA ([**Figures 7**](#f7){ref-type="fig"} and [**8**](#f8){ref-type="fig"}). With respect to the unconjugated bile acids, the concentrations of ursodeoxycholic acid (UDCA), lithocholic acid (LCA), DCA, beta-muricholic acid (βMCA), 3β-cholic acid (3β-CA), 7-ketholithocholic acid (7-ketoLCA), and 6,7-diketolithocholic acid (6,7-diketoLCA) were decreased, but 23-nordeoxycholic acid (Nor-DCA) were increased after OA administration compared with the control group. In regard to the conjugated bile acids, the concentrations of TCDCA, tauro-alpha-muricholic acid sodium salt (T-αMCA), tauro-beta-muricholic acid sodium salt (T-βMCA), and taurocholic acid (TCA) were increased (*P* \< 0.05), taurolithocholic acid (TLCA) was decreased (*P* \< 0.05) after OA administration compared with that of corresponding values in the control group. Collectively, bile acid changes were strongly related to OA-induced hepatotoxicity.

![Levels of unconjugated bile acids in liver samples after OA administration in C57BL/6J mice. Data are expressed as mean ± SEM (n = 6). ^\*^ *P* \< 0.05 *vs* the control group.](fphar-11-00747-g007){#f7}

![Levels of conjugated bile acids in liver samples after OA administration in C57BL/6J mice. Data are expressed as mean ± SEM (n = 6). ^\*^ *P* \< 0.05 *vs* the control group.](fphar-11-00747-g008){#f8}

We then examined the correlations between bile acids and serum biochemical factors ([**Figure 9**](#f9){ref-type="fig"}). The results were in accordance with the metabolomics analysis. ALT was positively correlated with GCA, TDCA, and T-βMCA, and negatively correlated with UDCA, chenodeoxycholic acid (CDCA), LCA, CA, DCA, and TLCA. ALP and TBA were positively correlated with TCDCA, GCA, and Nor-DCA, and negatively correlated with UDCA, CDCA, LCA, DCA, and TLCA.

![Correlation analysis results of liver bile acids and biochemical factors (ALT, AST, ALP, and TBA). Red squares indicate a positive correlation, and green squares indicate a negative correlation.](fphar-11-00747-g009){#f9}

Discussion {#s4}
==========

In this experiment, we observed that OA caused liver damage after given different doses, produced a dose-dependent increase in serum biochemical factors. To define the mechanism involved in OA hepatotoxicity. We firstly detected endogenous substances using the untargeted metabolomics approach and found that OA interfered bile acid, energy, and amino acid metabolism. Combined with the endogenous substances, biochemical analysis, and gallbladder morphology, bile acid components were then investigated by targeted metabolomics, the results unmasked that increased bile acids were the main factor leading to OA hepatotoxicity.

The liver plays a crucial role in amino acid metabolism, it is responsible for a large part of the overall amino acid synthesis and catabolism. The alteration of amino acid metabolism has recently is related to liver injury ([@B43]), and increased or decreased amino acids were as potential hepatotoxicity biomarkers ([@B2]). Similarly, compared with the control group, L-glutamic acid was decreased both in low- and high-dose groups ([**Figure 4**](#f4){ref-type="fig"}), suggesting that OA disturbed amino acid metabolism. Notably, other research suggested that valine and tryptophan were increased in animal models of liver injury ([@B26]; [@B6]), we found that valine and tryptophan increased in low dose but not significantly changed in high dose, which suggested that amino acid metabolism disorder caused by valine and tryptophan was not the main reason of OA liver toxicity.

The TCA cycle is an important hub related to carbohydrate, fat, and protein metabolism, of which impairments are closely associated with liver injury, impacting energy metabolism ([@B30]). Consistent with observations in *CCl4*-induced acute liver injury ([@B42]), elevated citraconic acid, succinate, and citric acid were observed in low- and high-dose groups ([**Figure 4**](#f4){ref-type="fig"}). According to the report ([@B44]), 4′-phosphopantetheine was a key intermediate in the production of CoA, which was positively correlated with ALT and AST. The increased level of 4′-phosphopantetheine also showed that OA destroyed energy metabolism. Overall, destroyed energy metabolism would potentially contribute to OA liver injury.

Apart from altered amino acid metabolism and energy metabolism, bile acid metabolism was similarly perturbed pathways after OA administration. Bile acids are synthesized from cholesterol in the liver, of which change can directly affect the metabolic state of the liver and indicate the degree of liver injury ([@B29]), the increased bile acids are considered as diagnostic markers of drug-induced cholestatic liver injury ([@B4]; [@B23]). The finding that levels of bile acids TCDCA, GCA were increased and TDCA was decreased in both low- and high-dose groups ([**Figure S2**](#SM2){ref-type="supplementary-material"}), DCA was increased in low dose group, we noted that TCDCA, GCA was positive with serum biochemical factors, while TDCA and DCA were negatively correlated with them. Although potential changes of bile acid composition in OA management mice have not been determined, it is attractive to speculate that bile acid homeostasis imbalance results in OA hepatotoxicity. In addition, elevated TBA, ALP as well as gallbladder morphology after OA administration ([**Figures 1**](#f1){ref-type="fig"} and [**2A**](#f2){ref-type="fig"}) may mostly reflect the bile acid homeostasis imbalance. Since it may be hypothesized that bile acid metabolism is the key metabolism pathway underlying OA-induced hepatotoxicity, the targeted metabolomics method was then implemented to further verify bile acid metabolism alterations.

Drugs caused cholestatic liver injury by changing the relative composition or concentration of the bile acids ([@B7]), characteristic as bile duct hyperplasia, necrosis, inflammatory cells, feathery degeneration, and steatosis. In terms of our observations, hepatocyte necrosis happened in low- and high-dose groups, but liver necrosis was more severe in the high dose group ([**Figure 2B**](#f2){ref-type="fig"}). Importantly, studies noted that increased bile acids such as CA, α/βMCA, GCA, TCDCA, TCA, and T-α/βMCA were regarded as diagnostic markers of cholestatic liver damage in the liver or serum ([@B22]; [@B32]; [@B34]). In our study, we found that the large proportion of conjugated bile acids (TDCA, TCDCA, TUDCA, GCA, and T-βMCA) were increased after OA administration ([**Figure 8**](#f7){ref-type="fig"}), and the overall content of unconjugated bile acids were decreased ([**Figure 7**](#f7){ref-type="fig"}), indicating that conjugated bile acids were the main contributors of OA hepatotoxicity, and while providing a reference for finding diagnostic indicators of OA hepatotoxicity. Moreover, it is known that cholestasis is caused by the imbalance of bile acids regulation, and Farnesoid X receptor (FXR) plays an important role in bile acids regulation, inhibition of FXR can augment the accumulation of bile acids in the liver, and subsequently cause liver injury ([@B14]; [@B28]), T-βMCA is a natural antagonist of FXR ([@B31]), the correlation analysis showed that T-βMCA were positively correlated with ALT ([**Figure 9**](#f8){ref-type="fig"}), implying that suppressed FXR was a key factor in OA hepatotoxicity, but further study is needed to confirm. Unexpectedly, conjugated bile acids TCA and T-βMCA only increased in the low-dose group and appeared to be decreased in the high-dose group ([**Figure 8**](#f7){ref-type="fig"}), possibly due to these bile acids that increased in serum or other tissues in the high dose group ([@B37]).

Surprisingly, unconjugated bile acids such as CA, DCA, CDCA, and LCA ([**Figure 9**](#f8){ref-type="fig"}) were negatively correlated with the ALT, TBA, and ALP, which was inconsistent with literature reports ([@B32]), but could be explained by unconjugated bile acids having little influence on OA hepatotoxicity. Furthermore, 3β-CA was increased in the low-dose group, decreased in the high-dose group, probably be considered as a defense mechanism liver injury caused by conjugated bile acids ([@B17]). In all, the changes of unconjugated bile acids further proved that the hepatotoxicity of OA was mainly caused by the accumulation of conjugated bile acids in the liver. Interestingly, in [**Figure 7**](#f7){ref-type="fig"}, DCA as well as other unconjugated bile acids changed in the high dose but not in [**Figure S2**](#SM2){ref-type="supplementary-material"}, and GCA was no significantly changed that was not similar to the [**Figure S2**](#SM2){ref-type="supplementary-material"}, the phenomenon may be explained by the results of matrix effect and the limited sample size in untargeted metabolomics analysis, which may have reduced the statistical power ([@B38]; [@B35]). Future studies can advance our findings by enlarging sample size or exploring the metabolites of serum and other tissues.

In conclusion, the above results demonstrated that OA destroyed energy, amino acid and bile acid metabolism. However, we have shown that bile acid metabolism is likely to be the most important pathway involved in the OA-induced liver injury ([**Figure S3**](#SM3){ref-type="supplementary-material"}). The bile acids (especially conjugated bile acids such as T-βMCA, TCA, and TCDCA) can be as the potential biomarkers, which may be helpful for further investigations of OA hepatotoxicity mechanism, as well as provide a reference basis for more studies on hepatotoxic drug mechanism.
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PCA score plots of C57BL/6J mice liver from different groups (n = 6, R^2^X = 0.593, Q^2^ 543 = 0.217).
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Detailed relative changes in the relative peak area of potential biomarkers. **(A)** Control group *vs* low-dose group, **(B)** Control group *vs* high-dose group. Data are expressed as mean ± SEM (n = 6). \**P* \< 0.05 vs the control group.
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Schematic diagram of OA hepatotoxicity.
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TUDCA, tauroursodeoxycholic acid; CDCA, chenodeoxycholic acid; CA, cholic acid; UDCA, ursodeoxycholic acid; DCA, deoxycholic acid; TCA, taurocholic acid; TCDCA, taurochenodeoxycholic acid; TDCA, taurodeoxycholic acid; αMCA, αmuricholic acid; βMCA, βmuricholic acid; TLCA, taurolithocholic acid; GCA, glycocholic acid; LCA, lithocholic acid; 6,7-diketoLCA, 6,7-diketolithocholic acid; 7-ketoLCA, 7-ketholithocholic acid; nor-DCA, 23-nordeoxycholic acid; λMCA, gamma muricholic acid; T-αMCA, tauro-alpha-muricholic acid sodium salt; T-βMCA, tauro-beta-muricholic acid sodium salt.
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